Clinicopathological characteristics of the surgical data set D4
| Non-MPR (N=41) | MPR (N=57) | Total (N=98) | P value | |
| Gender | ||||
| Male | 33 (80.5%) | 52 (91.2%) | 85 (86.7%) | 0.141 |
| Female | 8 (19.5%) | 5 (8.8%) | 13 (13.3%) | |
| Age | ||||
| Mean (SD) | 58.4 (9.85) | 60.7 (9.39) | 59.7 (9.60) | 0.249 |
| BMI | ||||
| Mean (SD) | 23.2 (2.88) | 22.6 (2.78) | 22.9 (2.82) | 0.363 |
| Missing | 1 (2.4%) | 2 (3.5%) | 3 (3.1%) | |
| Smoking | ||||
| Never smoked | 26 (63.4%) | 27 (47.4%) | 53 (54.1%) | 0.151 |
| Current or former smoker | 15 (36.6%) | 30 (52.6%) | 45 (45.9%) | |
| ECOG | ||||
| 0 | 36 (87.8%) | 55 (96.5%) | 91 (92.9%) | 0.126 |
| 1 | 5 (12.2%) | 2 (3.5%) | 7 (7.1%) | |
| Pathological type | ||||
| LUAD | 20 (48.8%) | 11 (19.3%) | 31 (31.6%) | 0.002 |
| LUSC | 17 (41.5%) | 44 (77.2%) | 61 (62.2%) | |
| NOS | 4 (9.8%) | 2 (3.5%) | 6 (6.1%) | |
| T stage | ||||
| T1 | 6 (14.6%) | 5 (8.8%) | 11 (11.2%) | 0.661 |
| T2 | 17 (41.5%) | 21 (36.8%) | 38 (38.8%) | |
| T3 | 11 (26.8%) | 17 (29.8%) | 28 (28.6%) | |
| T4 | 7 (17.1%) | 14 (24.6%) | 21 (21.4%) | |
| N stage | ||||
| N0 | 7 (17.1%) | 13 (22.8%) | 20 (20.4%) | 0.598 |
| N1 | 13 (31.7%) | 22 (38.6%) | 35 (35.7%) | |
| N2 | 19 (46.3%) | 21 (36.8%) | 40 (40.8%) | |
| N3 | 2 (4.9%) | 1 (1.8%) | 3 (3.1%) | |
| M stage | ||||
| M0 | 40 (97.6%) | 56 (98.2%) | 96 (98.0%) | 1.000 |
| M1 | 1 (2.4%) | 1 (1.8%) | 2 (2.0%) | |
| Clinical stage | ||||
| I | 1 (2.4%) | 4 (7.0%) | 5 (5.1%) | 0.706 |
| II | 8 (19.5%) | 14 (24.6%) | 22 (22.4%) | |
| III | 31 (75.6%) | 38 (66.7%) | 69 (70.4%) | |
| IV | 1 (2.4%) | 1 (1.8%) | 2 (2.0%) | |
| PD-L1 TPS | ||||
| <1% | 5 (12.2%) | 8 (14.0%) | 13 (13.3%) | 0.968 |
| 1–49% | 12 (29.3%) | 14 (24.6%) | 26 (26.5%) | |
| ≥50% | 9 (22.0%) | 13 (22.8%) | 22 (22.4%) | |
| Could not be evaluated | 15 (36.6%) | 22 (38.6%) | 37 (37.8%) | |
| ICIs | ||||
| Camrelizumab | 2 (4.9%) | 6 (10.5%) | 8 (8.2%) | 0.103 |
| Durvalumab | 2 (4.9%) | 0 (0%) | 2 (2.0%) | |
| Nivolumab | 26 (63.4%) | 28 (49.1%) | 54 (55.1%) | |
| Pembrolizumab | 5 (12.2%) | 13 (22.8%) | 18 (18.4%) | |
| Sintilimab | 3 (7.3%) | 1 (1.8%) | 4 (4.1%) | |
| Tislelizumab | 3 (7.3%) | 9 (15.8%) | 12 (12.2%) | |
| Course of preoperative therapy | ||||
| Two or less | 6 (14.6%) | 8 (14.0%) | 14 (14.3%) | 0.650 |
| Three | 31 (75.6%) | 39 (68.4%) | 70 (71.4%) | |
| Four or more | 4 (9.8%) | 10 (17.5%) | 14 (14.3%) | |
| Type of platinum therapy | ||||
| Not platinum-based regime | 2 (4.9%) | 4 (7.0%) | 6 (6.1%) | 0.888 |
| Carboplatin | 33 (80.5%) | 47 (82.5%) | 80 (81.6%) | |
| Cisplatin | 3 (7.3%) | 4 (7.0%) | 7 (7.1%) | |
| Lobaplatin | 3 (7.3%) | 2 (3.5%) | 5 (5.1%) | |
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; ICIs, immune checkpoint inhibitors; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MPR, major pathological response; NOS, not otherwise specified; PD-L1, programmed cell death-ligand 1; TPS, tumor proportion score.